CD37 ADC combined with CD20 monoclonal antibody in the treatment of DLBCL, clinical results are positive, Yi Mai Meng broke the news

Recent popular reports from Yimaike ★ Invitation to the event2021 Oncolytic Virus Drug Development Forum will open in Shanghai ★ The financing has reached hundreds of millions in half a year, and the oncolytic virus has entered the fast laneYimai New Observation Click on the picture and register now June 16, 2021 /Healthcare News eMedClub News/--Recently, Debiopharm, a global biopharmaceutical company, announced the Phase 2 results of Narratuximab emtansine antibody conjugate for the treatment of diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies
.

Non-Hodgkin’s Lymphoma (NHL) ranks 5th to 9th on the list of common cancers in most countries around the world.
It is estimated that there are more than 500,000 new cases in 2018.
The most common NHL is DLBCL
.

The need for many patients to improve the prognosis has led to the exploration of new treatment strategies beyond standard therapies, including treatments that target the CD37 antigen
.

 Naratuximab emtansine is an antibody-drug conjugate (ADC) targeting CD37, a potential new therapy for B cell malignancies
.

The new ADC drug uses its high affinity and specificity for CD37, and after binding with it, it selectively delivers the cytotoxic DM1 payload
.

After internalization, processing and intracellular release, DM1 hinders cell proliferation pathways, destroys microtubule assembly, and subsequently induces cell cycle arrest and apoptosis
.

The study is currently in phase 2b for R/R DLBCL treatment
.

The main measurement result of this open-label, multi-center adaptability study is the safety and effectiveness of co-administration of Naratuximab emtansine (anti-CD37 antibody) and rituximab (anti-CD20 antibody)
.

 In the phase 2 trial, the subjects were divided into two cohorts
.

Cohort A received intravenous injection every three weeks and received co-administration of naratuximab emtansine and rituximab at a dose of 0.
7 mg/kg on the first day of the 21-day cycle; at the same time, cohort B was administered within the 21-day cycle Received intravenous injection of Naratuximab emtansine with a total dose of 0.
8 mg/kg
.

 The breakthrough abstract published on EHA on June 12 showed that the results of the study showed significant efficacy and a high level of complete remission rate (CRR), especially in over-pretreated patients who had previously undergone two or more therapies , The curative effect of co-administration is more prominent
.

Dr.
Moshe Yair Levy, Director of Hematological Malignancies Research at Baylor University Medical Center, said: “For patients with DLBCL who are over-pretreated, their current options are limited, so the results of these trials are particularly exciting
.

High response rates and drug resistance.
Coupled with controllable safety, this provides us with strong theoretical support for further research on naratuximab emtansine in the treatment of B-cell malignancies
.

"About CD37 leukocyte antigen CD37 is a transmembrane protein of the four transmembrane protein superfamily
.

Under normal circumstances, CD37 antigen is only weakly expressed on T cells, bone marrow cells and granulocytes
.

However, CD37 is also expressed on some malignant B cells that cause NHL and chronic lymphocytic leukemia (CLL), indicating that CD37 can be used as a potential therapeutic target for B cell malignancies
.

There are currently many CD37 antibodies or ADCs in pre-clinical or early clinical stages abroad.
The editor has compiled a collection of foreign CD37 antibody drugs and scanned the QR code for a complete reading
.

There are still few domestic companies on this target
.

 For more details, scan the QR code to read the complete reference materials: 1.
https:// -for-the-treatment-of-b-cell-malignancies-301311534.
html Yimike has always been committed to the cutting-edge technology, industry trends, industry insights and other original news reports of bio-innovative drugs.
The high-end matrix users of all media have reached 160,000+.
Among them, industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.

In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.